Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adenocarcinoma of Lung~* Postoperative pathologic stage IB\~IIIA~* Complete surgical resection (R0 resection) N1-2: R0 resection with lobectomy and mediastinal lymph nodes dissection (MLND) N0: R0 resection with lobectomy with or without MLND~* Adjuvant treatment should start between 4 to 6 weeks after surgery~* ECOG performance status 0-1~* Weight loss during last 3 months should be less than 10%.~* Normal hematologic, hepatic and renal function Neutrophil count \> 1500 /microliter, Platelet \> 100,000/microliter, Hemoglobin \> 9 g/dL Bilirubin \<=1.5 x upper limit normal, transaminase \< 2.5 x upper limit normal Serum Creatinine \<=1.5 mg/dL~* Women in child bearing age should consent using contraceptive measures, and must have negative pregnancy test.~Exclusion Criteria:~* Other malignant neoplastic disease within 5 years.~* Neoadjuvant chemotherapy before surgery of lung cancer~* Patients who will be treated with postoperative radiation.~* Stage IIIB or IV lung cancer~* Severe infection, or cardiorespiratory, hematologic illness~* HIV positive cases~* Pregnancy or lactating women~* Autoimmune diseases or those who receiving immune suppressive treatment~* Symptomatic neuropathy \> CTCAE grade 1~* Those who consented other clinical trials within 3 months~* Other significant medical conditions contraindicated to clinical trial

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemebit plus Cisplatin (Type: EXPERIMENTAL): Pemetrexed (Pemebit 500 mg/m2) plus cisplatin (75 mg/m2) every 3 weeks up to 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).